BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15298635)

  • 1. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
    Armstrong D; Talley NJ; Lauritsen K; Moum B; Lind T; Tunturi-Hihnala H; Venables T; Green J; Bigard MA; Mössner J; Junghard O
    Aliment Pharmacol Ther; 2004 Aug; 20(4):413-21. PubMed ID: 15298635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.
    Johnsson F; Hatlebakk JG; Klintenberg AC; Román J; Toth E; Stubberöd A; Falk A; Edin R
    Scand J Gastroenterol; 2003 Apr; 38(4):354-9. PubMed ID: 12739706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
    Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
    Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of omeprazole and esomeprazole in patients suffering from bronchial asthma with associated gastroesophageal reflux disease].
    Maev IV; Viuchnova ES; Balashova NN; Shchekina MI
    Eksp Klin Gastroenterol; 2003; (3):26-31, 116. PubMed ID: 14556543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.
    Tsai HH; Chapman R; Shepherd A; McKeith D; Anderson M; Vearer D; Duggan S; Rosen JP;
    Aliment Pharmacol Ther; 2004 Sep; 20(6):657-65. PubMed ID: 15352914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: initial therapy of reflux disease with esomeprazole.
    Dent J
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():18-20. PubMed ID: 12614302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
    DeVault KR
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():33-9. PubMed ID: 16483268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances.
    Johnson D; Crawley JA; Hwang C; Brown K
    Aliment Pharmacol Ther; 2010 Jul; 32(2):182-90. PubMed ID: 20456306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of treatment response in patients with non-erosive reflux disease.
    Talley NJ; Armstrong D; Junghard O; Wiklund I
    Aliment Pharmacol Ther; 2006 Jul; 24(2):371-6. PubMed ID: 16842464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-erosive gastroesophageal reflux disease. Incidence of clinical forms, characteristics of esophageal exposure to acid and symptomatic correlations].
    Soto Pérez JC; Icaza ME; Vargas F; Valdovinos Díaz MA
    Rev Gastroenterol Mex; 2003; 68(2):113-9. PubMed ID: 15127647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.
    Johnson DA; Orr WC; Crawley JA; Traxler B; McCullough J; Brown KA; Roth T
    Am J Gastroenterol; 2005 Sep; 100(9):1914-22. PubMed ID: 16128933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease.
    Pace F; Negrini C; Wiklund I; Rossi C; Savarino V;
    Aliment Pharmacol Ther; 2005 Aug; 22(4):349-56. PubMed ID: 16098002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
    Thitiphuree S; Talley NJ
    Int J Clin Pract; 2000 Oct; 54(8):537-41. PubMed ID: 11198734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
    Eggleston A; Katelaris PH; Nandurkar S; Thorpe P; Holtmann G;
    Aliment Pharmacol Ther; 2009 May; 29(9):967-78. PubMed ID: 19210493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
    Carlsson R; Dent J; Watts R; Riley S; Sheikh R; Hatlebakk J; Haug K; de Groot G; van Oudvorst A; Dalväg A; Junghard O; Wiklund I
    Eur J Gastroenterol Hepatol; 1998 Feb; 10(2):119-24. PubMed ID: 9581986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.